2024
National Patterns of Hospital Admission Versus Home Recovery Following Mastectomy for Breast Cancer
Kim L, Moore M, Schneider E, Canner J, Ayyala H, Chen J, Anant P, Graetz E, Lynch M, Zanieski G, Gillego A, Valero M, Proussaloglou E, Berger E, Golshan M, Greenup R, Park T. National Patterns of Hospital Admission Versus Home Recovery Following Mastectomy for Breast Cancer. Annals Of Surgical Oncology 2024, 31: 9088-9099. PMID: 39322830, DOI: 10.1245/s10434-024-16107-w.Peer-Reviewed Original ResearchHR patientsLymph nodesRate of neoadjuvant chemotherapyHospital admissionNational patterns of careEmergency departmentDecrease wound complicationsNeoadjuvant chemo-Hospital re-admissionNeoadjuvant chemotherapyIn-hospital admissionRate of reconstructionPerioperative outcomesPostoperative hematomaComplication ratePostoperative complicationsWound complicationsHome recoveryPatterns of careBreast cancerMastectomyEmergency room visitsMultivariate analysisComplicationsPatientsASO Visual Abstract: Clipping the Positive Lymph Node in Patients with Clinically Node-Positive Breast Cancer Treated with Neoadjuvant Chemotherapy: Impact on Axillary Surgery in the ISPY-2 Clinical Trial
Switalla K, Boughey J, Dimitroff K, Yau C, Ladores V, Yu H, Tchou J, Golshan M, Ahrendt G, Postlewait L, Piltin M, Reyna C, Matsen C, Tuttle T, Wallace A, Arciero C, Lee M, Tseng J, Son J, Rao R, Sauder C, Naik A, Howard-McNatt M, Lancaster R, Norwood P, Esserman L, Mukhtar R. ASO Visual Abstract: Clipping the Positive Lymph Node in Patients with Clinically Node-Positive Breast Cancer Treated with Neoadjuvant Chemotherapy: Impact on Axillary Surgery in the ISPY-2 Clinical Trial. Annals Of Surgical Oncology 2024, 31: 7262-7263. DOI: 10.1245/s10434-024-15965-8.Peer-Reviewed Original ResearchClipping the Positive Lymph Node in Patients with Clinically Node Positive Breast Cancer Treated with Neoadjuvant Chemotherapy: Impact on Axillary Surgery in the ISPY-2 Clinical Trial
Switalla K, Boughey J, Dimitroff K, Yau C, Ladores V, Yu H, Tchou J, Golshan M, Ahrendt G, Postlewait L, Piltin M, Reyna C, Matsen C, Tuttle T, Wallace A, Arciero C, Lee M, Tseng J, Son J, Rao R, Sauder C, Naik A, Howard-McNatt M, Lancaster R, Norwood P, Esserman L, Mukhtar R. Clipping the Positive Lymph Node in Patients with Clinically Node Positive Breast Cancer Treated with Neoadjuvant Chemotherapy: Impact on Axillary Surgery in the ISPY-2 Clinical Trial. Annals Of Surgical Oncology 2024, 31: 7249-7259. PMID: 38995451, PMCID: PMC11452431, DOI: 10.1245/s10434-024-15792-x.Peer-Reviewed Original ResearchPositive lymph nodesEvent-free survivalNeoadjuvant chemotherapyAxillary surgeryClip placementLymph nodesPN+ diseasePositive nodesNode-positive breast cancer treated with neoadjuvant chemotherapyBreast cancer treated with neoadjuvant chemotherapyOmission of axillary dissectionSentinel lymph node biopsyClinically node-positiveNeoadjuvant chemotherapy trialsPathologically node-positiveLymph node biopsySurgical management strategiesProportion of patientsMultivariate logistic regressionNode-positiveAssociated with higher oddsCN+ patientsPre-NACNode biopsyAxillary dissectionInternal Mammary Lymphadenopathy Does Not Impact Oncologic Outcomes in Patients Treated with Neoadjuvant Chemotherapy: Results from the I-SPY2 Clinical Trial
Piltin M, Norwood P, Ladores V, Mukhtar R, Sauder C, Golshan M, Tchou J, Rao R, Lee M, Son J, Reyna C, Hewitt K, Kuerer H, Ahrendt G, Greenwalt I, Tseng J, Postlewait L, Howard-McNatt M, Jaskowiak N, Esserman L, Boughey J. Internal Mammary Lymphadenopathy Does Not Impact Oncologic Outcomes in Patients Treated with Neoadjuvant Chemotherapy: Results from the I-SPY2 Clinical Trial. Annals Of Surgical Oncology 2024, 31: 7420-7428. PMID: 38980586, DOI: 10.1245/s10434-024-15708-9.Peer-Reviewed Original ResearchPathological complete responseEvent-free survivalPatients treated with neoadjuvant chemotherapyNeoadjuvant chemotherapyDistant recurrenceLocoregional recurrenceOncological outcomesClinical trialsRate of locoregional recurrenceResponse to neoadjuvant chemotherapyInternal mammary lymphadenopathyModern neoadjuvant chemotherapyHigh tumor gradeMethodsWe evaluated patientsBreast cancer stageAxillary surgeryComplete responseMedian followTumor gradePretreatment imagingLarger tumorsPrognostic indicatorI-SPY2Comparing patientsCancer stage
2022
Long-term efficacy and safety of addition of carboplatin with or without veliparib to standard neoadjuvant chemotherapy in triple-negative breast cancer: 4-year follow-up data from BrighTNess, a randomized phase III trial
Geyer C, Sikov W, Huober J, Rugo H, Wolmark N, O’Shaughnessy J, Maag D, Untch M, Golshan M, Lorenzo J, Metzger O, Dunbar M, Symmans W, Rastogi P, Sohn J, Young R, Wright G, Harkness C, McIntyre K, Yardley D, Loibl S. Long-term efficacy and safety of addition of carboplatin with or without veliparib to standard neoadjuvant chemotherapy in triple-negative breast cancer: 4-year follow-up data from BrighTNess, a randomized phase III trial. Annals Of Oncology 2022, 33: 384-394. PMID: 35093516, DOI: 10.1016/j.annonc.2022.01.009.Peer-Reviewed Original ResearchConceptsTriple-negative breast cancerEvent-free survivalAddition of carboplatinNeoadjuvant chemotherapyOverall survivalHazard ratioBreast cancerEarly-stage triple-negative breast cancerPathological complete response rateRandomized phase III trialComplete response rateCyclophosphamide neoadjuvant chemotherapyManageable acute toxicitiesManageable safety profileSafety of additionUntreated stage IIStandard neoadjuvant chemotherapyPhase III trialsCo-primary endpointsLong-term efficacyAcute myeloid leukemiaWeekly paclitaxelPrimary endpointSecondary endpointsIII trials
2021
Matched cohort study of germline BRCA mutation carriers with triple negative breast cancer in brightness
Metzger-Filho O, Collier K, Asad S, Ansell PJ, Watson M, Bae J, Cherian M, O’Shaughnessy J, Untch M, Rugo HS, Huober JB, Golshan M, Sikov WM, von Minckwitz G, Rastogi P, Li L, Cheng L, Maag D, Wolmark N, Denkert C, Symmans WF, Geyer CE, Loibl S, Stover DG. Matched cohort study of germline BRCA mutation carriers with triple negative breast cancer in brightness. Npj Breast Cancer 2021, 7: 142. PMID: 34764307, PMCID: PMC8586340, DOI: 10.1038/s41523-021-00349-y.Peer-Reviewed Original ResearchTriple-negative breast cancerNeoadjuvant chemotherapyCohort studyBreast cancerInstability scoreGenomic instability scoreGermline BRCA mutation carriersPathologic complete response rateAddition of carboplatinComplete response rateStandard neoadjuvant chemotherapyLymph node statusBRCA mutation carriersGermline BRCA1/2 mutationsNegative breast cancerOverall cohortNode statusTreatment armsHigher oddsMutation carriersBRCA1/2 mutationsResponse rateCarboplatinPARP inhibitorsCancer119O Event-free survival (EFS), overall survival (OS), and safety of adding veliparib (V) plus carboplatin (Cb) or carboplatin alone to neoadjuvant chemotherapy in triple-negative breast cancer (TNBC) after ≥4 years of follow-up: BrighTNess, a randomized phase III trial
Loibl S, Sikov W, Huober J, Rugo H, Wolmark N, O'Shaughnessy J, Maag D, Untch M, Golshan M, Lorenzo J, Metzger O, Dunbar M, Symmans W, Geyer C. 119O Event-free survival (EFS), overall survival (OS), and safety of adding veliparib (V) plus carboplatin (Cb) or carboplatin alone to neoadjuvant chemotherapy in triple-negative breast cancer (TNBC) after ≥4 years of follow-up: BrighTNess, a randomized phase III trial. Annals Of Oncology 2021, 32: s408. DOI: 10.1016/j.annonc.2021.08.400.Peer-Reviewed Original ResearchASO Visual Abstract: Factors Associated with Nodal Pathologic Complete Response Among Breast Cancer Patients Treated with Neoadjuvant Chemotherapy: Results of CALGB 40601 (HER2+) and 40603 (Triple-Negative) (Alliance)
Weiss A, Campbell J, Ballman K, Sikov W, Carey L, Hwang E, Poppe M, Partridge A, Ollila D, Golshan M. ASO Visual Abstract: Factors Associated with Nodal Pathologic Complete Response Among Breast Cancer Patients Treated with Neoadjuvant Chemotherapy: Results of CALGB 40601 (HER2+) and 40603 (Triple-Negative) (Alliance). Annals Of Surgical Oncology 2021, 28: 436-437. DOI: 10.1245/s10434-021-10005-1.Peer-Reviewed Original ResearchFactors Associated with Nodal Pathologic Complete Response Among Breast Cancer Patients Treated with Neoadjuvant Chemotherapy: Results of CALGB 40601 (HER2+) and 40603 (Triple-Negative) (Alliance)
Weiss A, Campbell J, Ballman KV, Sikov WM, Carey LA, Hwang ES, Poppe MM, Partridge AH, Ollila DW, Golshan M. Factors Associated with Nodal Pathologic Complete Response Among Breast Cancer Patients Treated with Neoadjuvant Chemotherapy: Results of CALGB 40601 (HER2+) and 40603 (Triple-Negative) (Alliance). Annals Of Surgical Oncology 2021, 28: 5960-5971. PMID: 33821344, PMCID: PMC8532250, DOI: 10.1245/s10434-021-09897-w.Peer-Reviewed Original ResearchConceptsBreast pathologic complete responsePathologic complete responseResidual breast diseaseTriple-negative breast cancerNodal pathologic complete responsePretreatment nodal statusClinical nodal statusNeoadjuvant chemotherapyNodal statusAxillary surgeryComplete responseCALGB 40601YpN0 rateAxillary nodal involvementResidual nodal diseaseProportion of patientsCareful patient selectionBreast cancer patientsNAC regimensYpN0 diseaseYpN0 statusCN0 patientsNodal diseaseNodal involvementMultivariable analysisAssociation of Immunophenotype With Pathologic Complete Response to Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer
Filho OM, Stover DG, Asad S, Ansell PJ, Watson M, Loibl S, Geyer CE, Bae J, Collier K, Cherian M, O’Shaughnessy J, Untch M, Rugo HS, Huober JB, Golshan M, Sikov WM, von Minckwitz G, Rastogi P, Maag D, Wolmark N, Denkert C, Symmans WF. Association of Immunophenotype With Pathologic Complete Response to Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer. JAMA Oncology 2021, 7: 603-608. PMID: 33599688, PMCID: PMC7893540, DOI: 10.1001/jamaoncol.2020.7310.Peer-Reviewed Original ResearchConceptsTriple-negative breast cancerPathologic complete responseNeoadjuvant chemotherapyGene expression-based molecular subtypesComplete responseMolecular subtypesBreast cancerClinical trialsSecondary analysisStage IIEnd pointAddition of carboplatinClinical stage IIDe-escalate therapyHigh pCR ratePrespecified end pointPrespecified secondary analysisSecondary end pointsStandard neoadjuvant chemotherapySimilar baseline characteristicsSubset of patientsT cell infiltrationRandomized clinical trialsTumor cell proliferationWhole transcriptome RNA sequencing
2020
The impact of pattern of tumor response and other post-treatment histologic features on local recurrence in patients treated with neoadjuvant chemotherapy and breast conservation.
Laws A, Pastorello R, Choi J, Kantor O, Grossmith S, Schnitt S, Golshan M, Mittendorf E, King T. The impact of pattern of tumor response and other post-treatment histologic features on local recurrence in patients treated with neoadjuvant chemotherapy and breast conservation. Journal Of Clinical Oncology 2020, 38: 581-581. DOI: 10.1200/jco.2020.38.15_suppl.581.Peer-Reviewed Original ResearchPathologic complete responseResidual invasive diseaseLocal recurrenceNeoadjuvant chemotherapyBreast-conserving surgeryResidual DCISTumor responseResidual diseaseInvasive diseaseBreast pathologic complete responseDetailed pathology reviewAdjuvant endocrine therapyPoor prognostic factorModern systemic therapyTreatment effectsNeoadjuvant trastuzumabRCB scoreEndocrine therapyFree survivalMulticentric diseaseBreast conservationComplete responseLymphovascular invasionMargin statusPrognostic factors
2019
Immunophenotype and proliferation to predict for response to neoadjuvant chemotherapy in TNBC: Results from BrighTNess phase III study.
Metzger Filho O, Stover D, Asad S, Ansell P, Watson M, Loibl S, Geyer C, O'Shaughnessy J, Untch M, Rugo H, Huober J, Golshan M, Sikov W, Von Minckwitz G, Rastogi P, Maag D, Wolmark N, Denkert C, Symmans W. Immunophenotype and proliferation to predict for response to neoadjuvant chemotherapy in TNBC: Results from BrighTNess phase III study. Journal Of Clinical Oncology 2019, 37: 510-510. DOI: 10.1200/jco.2019.37.15_suppl.510.Peer-Reviewed Original ResearchPathologic complete responseNAC regimensNeoadjuvant chemotherapyPhase III studyT cell infiltrationClinico-pathologic variablesSignificant predictorsIII studyImmune signaturesComplete responseIndependent predictorsResearch biopsiesTNBC subtypesTotal macrophagesM2 macrophagesMultivariate analysisTNBCTumor proliferationImmunophenotypeTumorsBasal-likeRegimensChemotherapyCIBERSORTPAM50CALGB (Alliance) 40603: Long-term outcomes (LTOs) after neoadjuvant chemotherapy (NACT) +/- carboplatin (Cb) and bevacizumab (Bev) in triple-negative breast cancer (TNBC).
Sikov W, Polley M, Twohy E, Perou C, Singh B, Berry D, Tolaney S, Somlo G, Port E, Ma C, Kuzma C, Mamounas E, Golshan M, Bellon J, Collyar D, Hahn O, Hudis C, Winer E, Partridge A, Carey L. CALGB (Alliance) 40603: Long-term outcomes (LTOs) after neoadjuvant chemotherapy (NACT) +/- carboplatin (Cb) and bevacizumab (Bev) in triple-negative breast cancer (TNBC). Journal Of Clinical Oncology 2019, 37: 591-591. DOI: 10.1200/jco.2019.37.15_suppl.591.Peer-Reviewed Original ResearchTriple-negative breast cancerLong-term outcomesNeoadjuvant chemotherapyPoor outcomeResidual diseaseUntreated triple-negative breast cancerBetter long-term outcomesClinical stage IIDose-dense ACPretreatment clinical stageWeeks of paclitaxelPathologic complete responseResidual cancer burdenStandard neoadjuvant chemotherapyClinical trial informationBreast/axillaBetter EFSPrimary endpointStandard chemotherapyComplete responseTreatment armsCancer burdenChemotherapy dosesClinical stageTrial armsMagnetic resonance imaging for prediction of pathologic response to neoadjuvant chemotherapy in triple-negative breast cancer
Golshan M, Wong S, Loibl S, Huober J, O'Shaughnessy J, Rugo H, Wolmark N, McKee M, Maag D, Sullivan D, Metzger-Filho O, Von Minckwitz G, Geyer C, Sikov W, Untch M. Magnetic resonance imaging for prediction of pathologic response to neoadjuvant chemotherapy in triple-negative breast cancer. European Journal Of Surgical Oncology 2019, 45: e12-e13. DOI: 10.1016/j.ejso.2018.10.075.Peer-Reviewed Original ResearchTriple-negative breast cancerNeoadjuvant chemotherapyPathologic responseBreast cancerMagnetic resonanceChemotherapy
2017
Breast conservation after neoadjuvant chemotherapy for triple-negative breast cancer: Surgical results from an international randomized trial (BrighTNess).
Golshan M, Loibl S, Huober J, O'Shaughnessy J, Rugo H, Wolmark N, McKee M, Maag D, Sullivan D, Giranda V, Liu X, Von Minckwitz G, Geyer C, Sikov W, Untch M. Breast conservation after neoadjuvant chemotherapy for triple-negative breast cancer: Surgical results from an international randomized trial (BrighTNess). Journal Of Clinical Oncology 2017, 35: 514-514. DOI: 10.1200/jco.2017.35.15_suppl.514.Peer-Reviewed Original ResearchTriple-negative breast cancerNeoadjuvant systemic therapyBreast-conserving therapyBCT ratesBreast cancerSurgical assessmentOperable triple-negative breast cancerGermline BRCA mutation statusHigher mastectomy ratesInternational randomized trialsLarge prospective analysisBRCA mutation statusBCT eligibilityMastectomy ratesNeoadjuvant chemotherapySystemic therapyBreast conservationRandomized trialsSurgical managementSurgical resultsSurgical choicePatient's discretionProspective analysisMutation statusStage IIPhase 3 study evaluating efficacy and safety of veliparib (V) plus carboplatin (Cb) or Cb in combination with standard neoadjuvant chemotherapy (NAC) in patients (pts) with early stage triple-negative breast cancer (TNBC).
Geyer C, O'Shaughnessy J, Untch M, Sikov W, Rugo H, McKee M, Huober J, Golshan M, Giranda V, Von Minckwitz G, Maag D, Sullivan D, Wolmark N, McIntyre K, Ponce Lorenzo J, Metzger Filho O, Rastogi P, Symmans W, Liu X, Loibl S. Phase 3 study evaluating efficacy and safety of veliparib (V) plus carboplatin (Cb) or Cb in combination with standard neoadjuvant chemotherapy (NAC) in patients (pts) with early stage triple-negative breast cancer (TNBC). Journal Of Clinical Oncology 2017, 35: 520-520. DOI: 10.1200/jco.2017.35.15_suppl.520.Peer-Reviewed Original ResearchTriple-negative breast cancerPathologic complete responseBreast conservation surgeryNeoadjuvant chemotherapyAdverse eventsArm APO placeboArm BArm CEarly-stage triple-negative breast cancerStage triple-negative breast cancerInvasive triple-negative breast cancerSafety of veliparibPlacebo-controlled studyPhase 3 studyStandard neoadjuvant chemotherapyNon-prespecified analysisPotent PARP inhibitorNCI-CTCAENeoadjuvant paclitaxelPo bidQ3 weeksPrimary endpointSecondary endpointsBaseline characteristics
2013
Impact of neoadjuvant chemotherapy plus HER2-targeting on breast conservation rates: Surgical results from CALGB 40601 (Alliance).
Ollila D, Berry D, Cirrincione C, Carey L, Amos K, Henry N, Winer E, Hudis C, Golshan M. Impact of neoadjuvant chemotherapy plus HER2-targeting on breast conservation rates: Surgical results from CALGB 40601 (Alliance). Journal Of Clinical Oncology 2013, 31: 501-501. DOI: 10.1200/jco.2013.31.15_suppl.501.Peer-Reviewed Original ResearchNeoadjuvant therapyBCT candidatesCALGB 40601Neoadjuvant chemotherapySystemic therapySurgical resultsBreast surgeonsBreast cancerTumor-free surgical marginsBreast cancer ptsNeoadjuvant systemic therapyOperable breast cancerBreast conservation ratesPhase III trialsAnti-HER2 treatmentModern systemic therapyBreast cancer operationsBCT eligibilityCancer ptsEligible patientsNeoadjuvant trialsTherapy ratesIII trialsSurgical marginsCancer operations
2011
P2-08-02: Magnetic Resonance Imaging as a Predictor of Pathologic Response in Patients Treated with Neoadjuvant Systemic Treatment for Operable Breast Cancer (TBCRC 017).
De L, Cantor A, Mcguire K, Golshan M, Meric-Bernstam F, Horton J, Nanda R, Amos K, Forero A, Hudis C, Meszoely I, Hwang S. P2-08-02: Magnetic Resonance Imaging as a Predictor of Pathologic Response in Patients Treated with Neoadjuvant Systemic Treatment for Operable Breast Cancer (TBCRC 017). Cancer Research 2011, 71: p2-08-02-p2-08-02. DOI: 10.1158/0008-5472.sabcs11-p2-08-02.Peer-Reviewed Original ResearchRadiographic complete responseNeoadjuvant systemic therapyInvasive breast cancerSystemic therapyBreast cancerHR-/HER2Systemic treatmentTumor gradePathologic complete response rateTumor phenotypeBasis of estrogenComplete response rateOperable breast cancerMulticenter retrospective studyNeoadjuvant systemic treatmentMorbidity of surgeryHER2 receptor statusPrediction of pCRBreast cancer subtypesMagnetic resonance imagingHR-HER2IHC phenotypeChemotherapy regimenNeoadjuvant chemotherapyTN subtypeP2-15-01: Surgical Patterns of Care after Magnetic Resonance Imaging in the Academic Setting in Patients with Operable Breast Cancer Treated with Neoadjuvant Systemic Therapy: A Secondary Analysis of TBCRC 017.
De L, Cantor A, Mcguire K, Golshan M, Meric-Bernstam F, Horton J, Nanda R, Amos K, Forero A, Hudis C, Meszoely I, Hwang S. P2-15-01: Surgical Patterns of Care after Magnetic Resonance Imaging in the Academic Setting in Patients with Operable Breast Cancer Treated with Neoadjuvant Systemic Therapy: A Secondary Analysis of TBCRC 017. Cancer Research 2011, 71: p2-15-01-p2-15-01. DOI: 10.1158/0008-5472.sabcs11-p2-15-01.Peer-Reviewed Original ResearchNeoadjuvant systemic therapyT stageMastectomy ratesBreast conservationMRI responseJonckheere-Terpstra testChemotherapy regimenSystemic therapyCancer CenterSurgical patternsSecondary analysisBreast MRIHigher mastectomy ratesPotential response biomarkersT1-T2 patientsUse of mastectomyOperable breast cancerLarger tumor sizeHigher T stageComprehensive cancer centerLogistic regression analysisMagnetic resonance imagingNeoadjuvant chemotherapyNeoadjuvant therapyPreoperative chemotherapy
2004
Prediction of breast cancer size by ultrasound, mammography and core biopsy
Golshan M, Fung B, Wiley E, Wolfman J, Rademaker A, Morrow M. Prediction of breast cancer size by ultrasound, mammography and core biopsy. The Breast 2004, 13: 265-271. PMID: 15325659, DOI: 10.1016/j.breast.2004.05.005.Peer-Reviewed Original Research